These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 20421658)

  • 1. Prevalence of dyslipidaemia in patients treated with lipid-modifying drugs in the Netherlands. Part of the dyslipidaemia international survey.
    Strang AC; Kaasjager HA; Basart DC; Stroes ES
    Neth J Med; 2010 Apr; 68(4):168-74. PubMed ID: 20421658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
    Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
    Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent lipid abnormalities in patients treated with statins: Portuguese results of the Dyslipidemia International Study (DYSIS).
    da Silva PM; Cardoso SM;
    Rev Port Cardiol; 2011 Jan; 30(1):47-63. PubMed ID: 21425743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in Greece.
    Liberopoulos E; Vlasserou F; Mitrogianni Z; Papageorgantas I; Elisaf M;
    Angiology; 2012 Apr; 63(3):184-93. PubMed ID: 21676964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual dyslipidaemia after statin treatment in France: Prevalence and risk distribution.
    Ferrières J; Bérard E; Crisan O; Bongard V
    Arch Cardiovasc Dis; 2010 May; 103(5):302-9. PubMed ID: 20619240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain. DYSIS-Spain Study].
    González-Juanatey JR; Millán J; Alegría E; Guijarro C; Lozano JV; Vitale GC
    Rev Esp Cardiol; 2011 Apr; 64(4):286-94. PubMed ID: 21411216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total lipid management and cardiovascular disease in the dyslipidemia international study.
    Ferrières J; Amber V; Crisan O; Chazelle F; Jünger C; Wood D
    Cardiology; 2013; 125(3):154-63. PubMed ID: 23736147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study.
    Leiter LA; Lundman P; da Silva PM; Drexel H; Jünger C; Gitt AK;
    Diabet Med; 2011 Nov; 28(11):1343-51. PubMed ID: 21679231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).
    Zhao S; Wang Y; Mu Y; Yu B; Ye P; Yan X; Li Z; Wei Y; Ambegaonakr BM; Hu D;
    Atherosclerosis; 2014 Aug; 235(2):463-9. PubMed ID: 24950001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004.
    Ghandehari H; Kamal-Bahl S; Wong ND
    Am Heart J; 2008 Jul; 156(1):112-9. PubMed ID: 18585505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
    Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
    Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis.
    Petrella RJ; Merikle E; Jones J
    Clin Ther; 2007 Apr; 29(4):742-50. PubMed ID: 17617298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients.
    Bruckert E; Baccara-Dinet M; McCoy F; Chapman J
    Curr Med Res Opin; 2005 Dec; 21(12):1927-34. PubMed ID: 16368042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of obtaining national cholesterol education program adult treatment panel III goals for all major serum lipoproteins after initiation of lipid altering therapy.
    Nichols GA; Ambegaonkar BM; Sazonov V; Brown JB
    Am J Cardiol; 2009 Dec; 104(12):1689-94. PubMed ID: 19962476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid abnormalities and cardiovascular risk in the elderly.
    Milionis HJ; Elisaf MS; Mikhailidis DP
    Curr Med Res Opin; 2008 Mar; 24(3):653-7. PubMed ID: 18218195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statin-treated patients in ambulatory care.
    Bestehorn K; Smolka W; Pittrow D; Schulte H; Assmann G
    Curr Med Res Opin; 2010 Dec; 26(12):2833-9. PubMed ID: 21058895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of international guidelines on the management of cardiovascular risk factors in diabetic patients with peripheral arterial disease.
    Margeta C; Giurgea A; Hammer A; Schlager O; Zehetmayer S; Koppensteiner R; Willfort-Ehringer A
    Int Angiol; 2009 Jun; 28(3):175-80. PubMed ID: 19506537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.